Is it time to reconsider the locoregional approach in HER2+ breast cancer?

Philip Poortmans, MD, PhD, AZ Sint-Augustinus - Oncologisch Centrum GZA - Iridium Kankernetwerk, Antwerpen, Belgium, talks on whether treatment in early-stage HER2-positive breast cancer should be modified, highlighting de-escalation of locregional approaches. This interview took place at the European Society for Medical Oncology (ESMO) Breast Cancer 2022 congress in Berlin, Germany.